PJP prophylaxis with rituximab

Nature Reviews Rheumatology, Published online: 22 May 2023; doi:10.1038/s41584-023-00982-wIn a retrospective study, risk–benefit analyses suggest that primary prophylaxis against Pneumocystis jirovecii pneumonia is beneficial in patients receiving rituximab and high-dose glucocorticoids.

https://www.nature.com/articles/s41584-023-00982-w

Source: Nature Reviews Rheumatology - May 22, 2023 Category: Rheumatology Authors: Sarah Onuora Source Type: research

More News: Pneumonia | Rheumatology | Rituxan | Study